- HC Wainwright increased the price target on Genmab A/S (NASDAQ:GMAB) from $49 to $51, with a Buy rating.
- The analyst cites that Genmab recorded a Q2 diluted net income of DKK28.66 per share, better than the previously forecast diluted net income of DKK15.05.
- Genmab generated DKK 3.2 billion in revenue for 2Q22, with Darzalex royalties coming in at DKK 2.5 billion vs. HC’s estimates of DKK 3.1 billion and DKK 2.5 billion, respectively.
- Related Content: Genmab, BioNTech Join Forces For Cancer Immunotherapy Candidates.
- The analyst expects FY22 net earnings of DKK 64.71 per share vs. the prior estimate of DKK 64.14.
- “Given Darzalex’s strong growth trajectory and Genmab’s burgeoning pipeline, we believe that Genmab is well situated to weather further attrition given its profitability, strong balance sheet, solid positioning in multiple myeloma, and broad pipeline with multiple upcoming data catalysts,” said the HC Wainwright analyst.
- Price Action: GMAB shares are down 1.62% at $35.31 on the last check Monday.
Hess Midstream LP Announces Distribution Per Share Level Increase; Increases Quarterly Distribution From $0.5696 To $0.5851
Hess Midstream LP (NYSE:HESM) ("Hess Midstream"), today announced that the Board of Directors of its general partner declared a quarterly cash distribution of $0.5851 per Class A share for the quarter
